Several formulations combine a p-lactam antibiotic with a p-lactamase inhibitor (ampicillin-sulbactam [Unasyn], ticarcillin-clavulanic acid [Timentin], piper-acillin-tazobactam [Zosyn], and amoxicillin-clavulanic acid [Augmentin]). All of the p-lactamase inhibitor combinations except amoxicillin-clavulanic acid are parenteral formulations. Amoxicillin-clavulanic acid is the only combination drug with oral bioavailability. Elimination of the combination drugs occurs primarily by renal excretion. Therefore, all of the p-lactamase inhibitor combinations require dose adjustments in patients with renal insufficiency. The addition of the p-lactamase inhibitor significantly broadens the spectrum of antibacterial activity against p-lactamase-producing organisms. Consequently, these drugs have clinical use in treating infections with known or suspected mixed bacterial flora, such as biliary infections, diabetic foot ulcers, endomyometritis, and peritonitis.
Was this article helpful?
This guide will help millions of people understand this condition so that they can take control of their lives and make informed decisions. The ebook covers information on a vast number of different types of neuropathy. In addition, it will be a useful resource for their families, caregivers, and health care providers.